US Stock MarketDetailed Quotes
CDTX Cidara Therapeutics
- 11.2600
- +0.1100+0.99%
Close Oct 18 16:00 ET
79.25MMarket Cap-450P/E (TTM)
11.5800High10.3700Low42.88KVolume11.0100Open11.1500Pre Close485.63KTurnover1.02%Turnover RatioLossP/E (Static)7.04MShares24.400052wk High0.61P/B47.45MFloat Cap10.000052wk Low--Dividend TTM4.21MShs Float382.6000Historical High--Div YieldTTM10.85%Amplitude8.0000Historical Low11.3250Avg Price1Lot Size
Cidara Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -3,777.53%-103.78M | 39.03%-6.64M | 21.22%-22.43M | 39.42%-12.72M | -105.84%-1.63M | 123.84%2.82M | 53.84%-10.9M | -12.84%-28.47M | -40.89%-21M | 333.65%27.97M |
| Net income from continuing operations | -569.47%-91.21M | -442.71%-10.33M | 31.72%-22.93M | 67.31%-5.61M | -144.79%-6.71M | -3.85%-13.62M | 116.48%3.01M | 20.92%-33.58M | -2.14%-17.16M | 182.83%14.98M |
| Depreciation and amortization | 128.00%57K | 75.00%56K | -17.48%118K | 34.48%39K | -40.54%22K | 111.36%25K | -89.23%32K | 111.63%143K | 101.41%29K | -87.33%37K |
| Other non cash items | 3,994.83%2.26M | -70.15%220K | 26.27%1.24M | 116.76%266K | -85.57%295K | -111.09%-58K | 73,600.00%737K | 6,446.67%982K | -53,000.00%-1.59M | 102,150.00%2.05M |
| Change In working capital | -199.40%-15.59M | 117.04%2.61M | -963.44%-3.92M | -179.05%-8.25M | -60.66%3.96M | 5,093.38%15.68M | -120.02%-15.32M | -96.86%454K | -214.49%-2.96M | 104.84%10.07M |
| -Change in receivables | -77.44%4.66M | 144.19%8.97M | -2,083.02%-10.41M | -1,592.92%-13.39M | 1,351.43%2.63M | 422.35%20.64M | -492.00%-20.29M | -108.20%-477K | 46.70%-791K | 70.63%-210K |
| -Change in inventory | 404.40%7.27M | ---1.17M | ---6.1M | ---3.63M | ---79K | ---2.39M | --0 | --0 | --0 | --0 |
| -Change in prepaid assets | -68.87%396K | -132.19%-273K | 253.07%3.74M | 223.26%959K | -27.51%656K | 187.91%1.27M | 175.71%848K | -965.50%-2.44M | 17.41%-778K | -63.89%905K |
| -Change in payables and accrued expense | -44.37%731K | -165.83%-2.27M | 877.89%15.39M | 251.90%9.19M | 359.39%1.44M | 215.26%1.31M | 425.57%3.45M | 244.01%1.57M | 1,025.89%2.61M | -153.94%-554K |
| -Change in other current liabilities | 6.23%-286K | 32.07%-197K | 7.51%-973K | 17.82%-166K | 27.15%-212K | -7.77%-305K | -5.07%-290K | -168.71%-1.05M | -109.35%-202K | -66.29%-291K |
| -Change in other working capital | -485.00%-28.36M | -354.86%-2.44M | -295.30%-5.56M | 68.22%-1.21M | -104.58%-468K | -522.21%-4.85M | 134.22%957K | -66.12%2.85M | -221.32%-3.8M | 349.63%10.22M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -3,777.53%-103.78M | 39.03%-6.64M | 21.22%-22.43M | 39.42%-12.72M | -105.84%-1.63M | 123.84%2.82M | 53.84%-10.9M | -12.84%-28.47M | -40.89%-21M | 333.65%27.97M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 75.53%-23K | -327.97%-505K | -1,877.78%-178K | -1,300.00%-126K | -568.75%-107K | -11.90%-94K | -187.80%-118K | -9K | 25.00%-9K |
| Net PPE purchase and sale | --0 | 75.53%-23K | -327.97%-505K | -1,877.78%-178K | -1,300.00%-126K | -568.75%-107K | -11.90%-94K | -187.80%-118K | ---9K | 25.00%-9K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | 75.53%-23K | -327.97%-505K | -1,877.78%-178K | -1,300.00%-126K | -568.75%-107K | -11.90%-94K | -187.80%-118K | ---9K | 25.00%-9K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 91,721.07%239.13M | -100.35%-93K | 2,832.28%25.98M | -98.80%8K | 0 | 76.51%-261K | 4,394.11%26.24M | -102.13%-951K | -98.20%664K | 113.21%107K |
| Net issuance payments of debt | ---75K | ---50K | --0 | --0 | --0 | --0 | --0 | 41.65%-2.59M | --0 | 66.61%-371K |
| Net common stock issuance | 91,748.28%239.2M | --0 | 999.20%25.96M | -99.85%1K | --0 | ---261K | 5,144.60%26.22M | -95.18%2.36M | -98.25%664K | 298.01%1.2M |
| Proceeds from stock option exercised by employees | --0 | --0 | --21K | --7K | --0 | --0 | --14K | --0 | --0 | --0 |
| Net other financing activities | --4K | ---43K | ---- | ---- | ---- | ---- | ---- | ---720K | --0 | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 91,721.07%239.13M | -100.35%-93K | 2,832.28%25.98M | -98.80%8K | --0 | 76.51%-261K | 4,394.11%26.24M | -102.13%-951K | -98.20%664K | 113.21%107K |
| Net cash flow | ||||||||||
| Beginning cash position | -39.52%29.02M | 9.31%35.78M | -47.44%32.73M | -8.30%48.67M | 101.66%50.43M | 26.35%47.98M | -47.44%32.73M | 44.99%62.27M | 31.69%53.08M | -52.90%25.01M |
| Current changes in cash | 5,415.53%135.35M | -144.34%-6.76M | 110.31%3.05M | 36.64%-12.89M | -106.27%-1.76M | 118.93%2.45M | 162.73%15.25M | -252.88%-29.54M | -192.62%-20.35M | 319.41%28.07M |
| End cash Position | 225.93%164.37M | -39.52%29.02M | 9.31%35.78M | 9.31%35.78M | -8.30%48.67M | 101.66%50.43M | 26.35%47.98M | -47.44%32.73M | -47.44%32.73M | 31.69%53.08M |
| Free cash flow | -3,922.47%-103.78M | 39.35%-6.67M | 19.78%-22.94M | 38.60%-12.9M | -106.29%-1.76M | 122.91%2.72M | 53.60%-10.99M | -13.13%-28.59M | -40.95%-21.01M | 333.34%27.96M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data